Jared Kaltwasser

The partnership between the North Dakota healthcare system and Orexo, a Swedish digital therapeutics company, may be an example of how digital therapeutics can be especially beneficial for healthcare systems serving rural areas.

The new device collects some information automatically but also relies on patient reports of measures like well-being.

Serge Marchand, Ph.D., of Lucine told his employer that doing scientifically rigorous trials of digital therapeutics was “going to take a little longer, and it's going to be costly.”

The confusing, data-intensive world of getting help with medical bills has become a fertile territory for software developers.

Akili says the underlying technology of its AKL-TO1 product (marketed in the U.S. as EndeavorRx) is “disease agnostic” and may be used as a treatment for a variety of conditions.

The arrangement represents both a solution to an unmet medical need and a new market opportunity for the digital therapeutics firm.

Decreased hormone levels appear to increase the risk of key symptoms of obstructive sleep apnea (OSA).

The virtual format is catching on but has important limitations which make it unsuitable in certain situations.

Women traveling out of state for a medication abortion may wind up using telehealth.

The new report adds to a growing body of evidence suggesting links between sleep and cardiovascular health.

The new assessment is supposed to better gauge whether people are getting quality sleep.

The research findings confirm that nine hours of sleep is an important benchmark for elementary-age children.

Interviews with people with myeloproliferative neoplasms show almost all of them often feel fatigued — and that they must manage the problem on their own.

The new report is believed to be among the first to examine cardiovascular risk in myeloproliferative neoplasms through a genetic lens. Mutations in the CALR gene may restore vascular dysfunction in some patients.

Like many digital therapeutics, the Better Therapeutics product is based on techniques used in cognitive behavioral therapy. The prescription digital therapeutic is designed to help people with diabetes modify their behaviors and eating patterns to bring down their A1c levels.

Patients use a smartphone camera to read results from a test strip. An app uses colorimetric analysis, computer vision and artificial intelligence to interpret the results.

Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite. But their cost-effectiveness is in question, and many payers are saying no to coverage — for now.

A systematic review shows as many as one-third of people with opioid use disorder have concurrent depression, and one-third will have antisocial personality disorder over the course of their lifetimes.

Although one in 12 controlled substances medication transactions at US hospitals involve suspicious variations, only about half of such transactions are ever investigated.

New technology could make it possible to get complex sleep analytics at home. The question is whether physicians will accept the device.

The report suggests that smoking by fathers could lead to alterations in their offspring. Male offspring may be more susceptible than female offspring.

People with common sleep disorders tended to have higher scores on a depression assessment, a study shows.

The report highlights the gap between rigorously tested prescription digital therapeutics and products that make health or economic claims without providing supportive evidence.

The results were surprising, since other studies have suggested people who have sleep disruptions do not respond as robustly to vaccines.

The partnership between the alliance and the Healthware Group is aimed at harmonizing assessment criteria and regulatory pathways in Europe.

Patients using the prescription digital therapeutic saw a decrease of $3,591 in healthcare costs in the six months following treatment initiation.

People who are incarcerated often lack access to a range of opioid use disorder treatments, even though treatment while incarcerated can lead to better outcomes once they are released.

Males and older patients were particularly vulnerable, the study found.

The findings paint a mixed picture, though, as stimulant use in patients with OUD was also associated with an increased risk of drug poisoning.

The company is producing repair kits and replacement devices, but those efforts have led to a shortage of devices.